MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.85
-0.63
-2.68%
Pre Market: 23.00 +0.15 +0.66% 08:09 06/18 EDT
OPEN
23.28
PREV CLOSE
23.48
HIGH
26.68
LOW
21.78
VOLUME
46
TURNOVER
--
52 WEEK HIGH
94.17
52 WEEK LOW
18.72
MARKET CAP
1.81B
P/E (TTM)
90.21
1D
5D
1M
3M
1Y
5Y
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG (OTC: RHHBY) of $50 million. Under the license agreement, Roche a...
Benzinga · 1d ago
BRIEF-Atea Pharmaceuticals Announces Achievement Of At-527 Development Milestone Under License Agreement With Roche
reuters.com · 2d ago
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that it has achieved a milestone associated with the d...
GlobeNewswire · 2d ago
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB...
GlobeNewswire · 3d ago
Perceptive Advisors Llc Buys Mirati Therapeutics Inc, BridgeBio Pharma Inc, SpringWorks ...
GuruFocus News · 06/10 20:38
Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman ...
GlobeNewswire · 05/26 12:09
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)
Zacks.com · 05/25 04:41
INSIGHT-Inside the race to find a COVID-19 treatment pill
reuters.com · 05/21 09:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVIR. Analyze the recent business situations of Atea Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVIR stock price target is 35.00 with a high estimate of 35.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 52.10M
% Owned: 65.75%
Shares Outstanding: 79.24M
TypeInstitutionsShares
Increased
24
4.52M
New
17
334.45K
Decreased
24
2.34M
Sold Out
5
319.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.27%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Jean-Pierre Sommadossi
Chief Financial Officer/Executive Vice President/Secretary
Andrea Corcoran
Senior Vice President - Finance
Wayne Foster
Other
Janet Hammond
Senior Vice President
Jonae Barnes
Other
Maria Horga
Other
John Vavricka
Other
Arantxa Horga
Lead Director/Independent Director
Franklin Berger
Director
Jerome Adams
Independent Director
Barbara Duncan
Independent Director
Andrew Hack
Independent Director
Bruno Lucidi
Independent Director
Polly Murphy
Independent Director
Bruce Polsky
No Data
  • All
  • Financials
  • Insiders
More
About AVIR
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV). Its purine nucleotide prodrug platform develops treatments for life threatening diseases caused by single stranded ribonucleic acid (ssRNA) viral infections. Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients with COVID-19. It is developing AT-752, an oral, purine nucleoside prodrug product candidate for the treatment of dengue. It is also developing AT-787 for the treatment of chronic HCV infection, including patients with decompensated cirrhosis. It is evaluating AT-889 and other candidates for the treatment of RSV.

Webull offers kinds of Atea Pharmaceuticals Inc stock information, including NASDAQ:AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.